Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Pentamidine is a clinically available anti-protozoal agent, which also inhibits the interaction of wild type p53 and S100B;these are frequently expressed in melanomas. The primary objective is to determine the response rate of relapsed and/or refractory melanoma that has previously been defined to express detectable S100B and to have a wild-type p53 mutation. Secondary objectives include assessment of toxicities, observation of time to disease progression, and observation of effect of drug treatment on expression of S100B and p53.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR016500-08
Application #
7951182
Study Section
Special Emphasis Panel (ZRR1-CR-3 (02))
Project Start
2009-03-01
Project End
2010-06-30
Budget Start
2009-03-01
Budget End
2010-06-30
Support Year
8
Fiscal Year
2009
Total Cost
$9,629
Indirect Cost

  Institution

Name
University of Maryland Baltimore
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
188435911
City
Baltimore
State
MD
Country
United States
Zip Code
21201

  Publications

Cedillo-Couvert, Esteban A; Ricardo, Ana C; Chen, Jinsong et al. (2018) Self-reported Medication Adherence and CKD Progression. Kidney Int Rep 3:645-651
Cedillo-Couvert, Esteban A; Hsu, Jesse Y; Ricardo, Ana C et al. (2018) Patient Experience with Primary Care Physician and Risk for Hospitalization in Hispanics with CKD. Clin J Am Soc Nephrol 13:1659-1667
Drawz, Paul E; Brown, Roland; De Nicola, Luca et al. (2018) Variations in 24-Hour BP Profiles in Cohorts of Patients with Kidney Disease around the World: The I-DARE Study. Clin J Am Soc Nephrol 13:1348-1357
Schrauben, Sarah J; Hsu, Jesse Y; Rosas, Sylvia E et al. (2018) CKD Self-management: Phenotypes and Associations With Clinical Outcomes. Am J Kidney Dis 72:360-370
Rahman, Mahboob; Hsu, Jesse Yenchih; Desai, Niraj et al. (2018) Central Blood Pressure and Cardiovascular Outcomes in Chronic Kidney Disease. Clin J Am Soc Nephrol 13:585-595
Wrobleski, Margaret M; Parker, Elizabeth A; Hurley, Kristen M et al. (2018) Comparison of the HEI and HEI-2010 Diet Quality Measures in Association with Chronic Disease Risk among Low-Income, African American Urban Youth in Baltimore, Maryland. J Am Coll Nutr 37:201-208
Bundy, Joshua D; Bazzano, Lydia A; Xie, Dawei et al. (2018) Self-Reported Tobacco, Alcohol, and Illicit Drug Use and Progression of Chronic Kidney Disease. Clin J Am Soc Nephrol 13:993-1001
Bansal, Nisha; Xie, Dawei; Sha, Daohang et al. (2018) Cardiovascular Events after New-Onset Atrial Fibrillation in Adults with CKD: Results from the Chronic Renal Insufficiency Cohort (CRIC) Study. J Am Soc Nephrol 29:2859-2869
Harhay, Meera N; Xie, Dawei; Zhang, Xiaoming et al. (2018) Cognitive Impairment in Non-Dialysis-Dependent CKD and the Transition to Dialysis: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 72:499-508
Bansal, Nisha; Roy, Jason; Chen, Hsiang-Yu et al. (2018) Evolution of Echocardiographic Measures of Cardiac Disease From CKD to ESRD and Risk of All-Cause Mortality: Findings From the CRIC Study. Am J Kidney Dis 72:390-399

Showing the most recent 10 out of 411 publications